Day One Biopharmaceuticals (DAWN)

• Market cap: $1.28B
• 1 day: -0.16%
• 5 days: -0.08%
• 1 month: -5.59%
• 3 months: -11.65%
• 6 months: -6.36%
• Year to date: -12.74%
• 1 year: -17.57%
• 5 years: -51.06%
• 10 years: -51.06%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Employees: 174

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 36

30% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 27

24% more capital invested

Capital invested by funds: $1.03B [Q2] → $1.28B (+$249M) [Q3]

19.0% more ownership

Funds ownership: 85.56% [Q2] → 104.56% (+19.0%) [Q3]

5% more funds holding

Funds holding: 155 [Q2] → 163 (+8) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

48% less call options, than puts

Call options by funds: $2.17M | Put options by funds: $4.16M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $33 160% upside
• Avg. target: $36 182% upside
• High target: $40 216% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading	168% upside $34	Buy Maintained	17 Dec 2024
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 13 / 46 met price target	216% upside $40	Buy Reiterated	31 Oct 2024
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target	160% upside $33	Buy Reiterated	31 Oct 2024